(Q37353919)

19 August 2017

1 reference

title

Recent advances in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (English)

1 reference

19 August 2017

1 reference

Masamitsu Yanada

1

1 reference

19 August 2017

Ryuzo Ohno

series ordinal

2

1 reference

19 August 2017

Tomoki Naoe

series ordinal

3

1 reference

19 August 2017

language of work or name

1 reference

18 December 2008

1 reference

International Journal of Hematology

19 August 2017

published in

1 reference

19 August 2017

volume

89

1 reference

19 August 2017

issue

1

1 reference

19 August 2017

page(s)

3-13

1 reference

Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study

19 August 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS12185-008-0223-Z

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

21 January 2018

1 reference

12 December 2020

Prediction of risk of disease recurrence by genome-wide cDNA microarray analysis in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib-combined chemotherapy

1 reference

12 December 2020

Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95-01.

1 reference

12 December 2020

Risk factors for adults with Philadelphia-chromosome-positive acute lymphoblastic leukaemia in remission treated with allogeneic bone marrow transplantation: the potential of real-time quantitative reverse-transcription polymerase chain reaction.

1 reference

12 December 2020

Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia

1 reference

12 December 2020

A novel abl protein expressed in Philadelphia chromosome positive acute lymphoblastic leukaemia positive acute lymphoblastic leukaemia

1 reference

12 December 2020

Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche de

1 reference

12 December 2020

Cytogenetic abnormalities in adult acute lymphoblastic leukemia: correlations with hematologic findings outcome. A Collaborative Study of the Group Français de Cytogénétique Hématologique

1 reference

12 December 2020

Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).

1 reference

12 December 2020

Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of induction

1 reference

12 December 2020

Long-term follow-up of allogeneic bone marrow recipients for Philadelphia chromosome-positive acute lymphoblastic leukemia.

1 reference

12 December 2020

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

1 reference

12 December 2020

In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants

1 reference

12 December 2020

Long-term remission of Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation from matched sibling donors: a 20-year experience with the fractionated total body irradiation-etoposide regimen

1 reference

12 December 2020

Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia.

1 reference

12 December 2020

Bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia.

1 reference

12 December 2020

A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811.

1 reference

12 December 2020

Purging in BCR-ABL-positive acute lymphoblastic leukemia using immunomagnetic beads: comparison of residual leukemia and purging efficiency in bone marrow vs peripheral blood stem cells by semiquantitative polymerase chain reaction

1 reference

12 December 2020

The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia

1 reference

12 December 2020

Predictors of relapse and overall survival in Philadelphia chromosome-positive acute lymphoblastic leukemia after transplantation

1 reference

12 December 2020

Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: results of Southwest Oncology Group 9400 study

1 reference

12 December 2020

Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemia

1 reference

12 December 2020

Important therapeutic targets in chronic myelogenous leukemia

1 reference

12 December 2020

Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia

1 reference

12 December 2020

Expression of a distinctive BCR-ABL oncogene in Ph1-positive acute lymphocytic leukemia (ALL).

1 reference

12 December 2020

Bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia

1 reference

12 December 2020

Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia

1 reference

12 December 2020

VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo

1 reference

12 December 2020

Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.

1 reference

12 December 2020

Early response to induction is predictive of survival in childhood Philadelphia chromosome positive acute lymphoblastic leukaemia: results of the Medical Research Council ALL 97 trial

1 reference

12 December 2020

Overriding imatinib resistance with a novel ABL kinase inhibitor

1 reference

12 December 2020

Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL)

1 reference

12 December 2020

1 reference

12 December 2020

Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study

1 reference

12 December 2020

Precise quantification of minimal residual disease at day 29 allows identification of children with acute lymphoblastic leukemia and an excellent outcome

1 reference

12 December 2020

A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias

1 reference

12 December 2020

Prospective karyotype analysis in adult acute lymphoblastic leukemia: the cancer and leukemia Group B experience

1 reference

12 December 2020

Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer--Childhood Leukemia Cooperative Group

1 reference

12 December 2020

Optimizing therapy of chronic myeloid leukemia

1 reference

12 December 2020

MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation

1 reference

12 December 2020

Philadelphia chromosome-positive (Ph+) childhood acute lymphoblastic leukemia: good initial steroid response allows early prediction of a favorable treatment outcome.

1 reference

12 December 2020

Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia

1 reference

12 December 2020

Relationship between minimal residual disease and outcome in adult acute lymphoblastic leukemia.

1 reference

12 December 2020

Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)

1 reference

12 December 2020

Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia.

1 reference

12 December 2020

In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells

1 reference

12 December 2020

Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia

1 reference

12 December 2020

Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL)

1 reference

12 December 2020

Karyotype at diagnosis is the major prognostic factor predicting relapse-free survival for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib-combined chemotherapy

1 reference

12 December 2020

Unique fusion of bcr and c-abl genes in Philadelphia chromosome positive acute lymphoblastic leukemia

1 reference

12 December 2020

Long-term follow-up of patients with newly diagnosed adult acute lymphoblastic leukemia: a single institution experience of 378 consecutive patients over a 21-year period

1 reference

12 December 2020

Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood.

1 reference

12 December 2020

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

1 reference

12 December 2020

Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trials

1 reference

12 December 2020

Myeloablative allogeneic hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia in adults: significant roles of total body irradiation and chronic graft-versus-host disease

1 reference

12 December 2020

High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group

1 reference

12 December 2020

NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia

1 reference

12 December 2020

Prospective monitoring of BCR-ABL1 transcript levels in patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia undergoing imatinib-combined chemotherapy

1 reference

12 December 2020

Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia--results of the prospective multicenter LALA-94 trial

1 reference

12 December 2020

A potential graft-versus-leukemia effect after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: results from the French Bone Marrow Transplantation Society.

1 reference

12 December 2020

ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party o

1 reference

12 December 2020

Patients' age and BCR-ABL frequency in adult B-precursor ALL: a retrospective analysis from the GMALL study group

1 reference

12 December 2020

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis

1 reference

12 December 2020

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

1 reference

12 December 2020

Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate

1 reference

12 December 2020

Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study.

1 reference

12 December 2020

Cytogenetics adds independent prognostic information in adults with acute lymphoblastic leukaemia on MRC trial UKALL XA. MRC Adult Leukaemia Working Party.

1 reference

12 December 2020

Minimal residual disease in adolescent (older than 14 years) and adult acute lymphoblastic leukemias: early immunophenotypic evaluation has high clinical value.

1 reference

12 December 2020

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

1 reference

12 December 2020

Induction therapy by frequent administration of doxorubicin with four other drugs, followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia: the JALSG-ALL93 study

1 reference

12 December 2020

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

12 December 2020

Strategies for overcoming imatinib resistance in chronic myeloid leukemia

1 reference

12 December 2020

Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis.

1 reference

12 December 2020

Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial

1 reference

12 December 2020

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

1 reference

12 December 2020

Clinical effect of imatinib added to intensive combination chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia

1 reference

12 December 2020

10.1007/S12185-008-0223-Z

Identifiers

DOI

1 reference

19 August 2017

1 reference